Alternate stent CAF design for TAVR

Information

  • Patent Grant
  • 11672654
  • Patent Number
    11,672,654
  • Date Filed
    Monday, July 20, 2020
    4 years ago
  • Date Issued
    Tuesday, June 13, 2023
    a year ago
Abstract
A prosthetic heart valve includes a stent extending in a longitudinal direction and having a collapsed condition and an expanded condition. The stent includes a plurality of struts forming cells and a plurality of commissure attachment features spaced apart in an annular direction of the stent and extending in a medial direction of the stent. A valve assembly is secured to the commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position. A method of manufacturing the prosthetic heart valve is also provided.
Description
BACKGROUND OF THE INVENTION

The present invention relates to collapsible prosthetic heart valves, and more particularly, to prosthetic heart valves having commissure attachment features that reduce strain on the leaflets of the prosthetic valve and methods of manufacturing the commissure attachment features.


Diseased and/or defective heart valves may lead to serious health complications. One method of addressing this condition is to replace a non-functioning heart valve with a prosthetic valve. Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open-chest, open-heart surgery.


Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve must first be collapsed to reduce its circumferential size.


When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be repaired by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and expanded to its full operating size. For balloon-expandable valves, this generally involves releasing the entire valve, assuring its proper location and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the stent is withdrawn from the delivery apparatus.


Properly functioning prosthetic heart valves maintain unidirectional blood flow in the circulatory system by opening and closing, depending on the difference in the pressure on opposite sides of the valve. Prosthetic aortic heart valves prevent backflow from the aorta into the left ventricle during systole.


Despite the improvements that have been made to prosthetic heart valves, various shortcomings remain. For example, prosthetic heart valves have limited life expectancies for a variety of reasons. Thrombus buildup, for example, may prevent the prosthetic leaflets from properly coapting. Moreover, the prosthetic heart valve may be susceptible to failure at high stress regions, such as the leaflet commissure attachment feature, causing the prosthetic leaflets to tear and/or the sutures that attach the prosthetic valve assembly to the stent to tear.


Therefore, there is a need for improvements to the commissure attachment features of prosthetic heart valves that adequately secure the prosthetic leaflets to the stent in a manner that reduces the strain placed on the valve assembly without affecting the prosthetic heart valve's ability to collapse.


BRIEF SUMMARY OF THE INVENTION

In accordance with a first aspect of the present invention, a commissure attachment feature extends in a medial direction of a stent for coupling a valve assembly to the stent. Among other advantages, this attachment feature permits adjacent leaflets to be sutured to one another to improve blood washout of the neo-sinus of the prosthetic heart valve to prevent the formation of thrombus, and to redistribute strain from the commissure of the leaflets to the stent. Redistributing the strain in this manner reduces the likelihood that the prosthetic leaflets will tear.


One embodiment of the device includes a stent extending in a longitudinal direction and having a collapsed condition and an expanded condition. The stent includes a plurality of struts forming cells and a plurality of commissure attachment features spaced apart in an annular direction of the stent. Each of the commissure attachment features is attached to select ones of the struts and extends in a medial direction of the stent. A valve assembly is secured to the plurality of commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position.


A method of manufacturing a prosthetic heart valve is also provided. The method includes cutting a tubular material to form a stent, the stent extending in a longitudinal direction and having a collapsed condition and an expanded condition. The stent includes a plurality of struts forming cells and a plurality of commissure attachment features spaced apart in an annular direction of the stent. The method further includes bending each of the commissure attachment features from a first orientation to a second orientation different from the first orientation, and coupling a valve assembly to the commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments of the present invention are described herein with reference to the drawings, wherein:



FIG. 1 is a side elevational view of a collapsible prosthetic heart valve in accordance with the prior art;



FIG. 2 is a highly schematic cutaway view of the prosthetic heart valve of FIG. 1 disposed within the aortic valve annulus of patient;



FIG. 3 is a highly schematic top view of the prosthetic heart valve of FIG. 1 showing the commissure of adjacent leaflets sutured together;



FIG. 4 is a side elevational view of a collapsible prosthetic heart valve in accordance with an embodiment of the present invention;



FIG. 5 is a highly schematic cross-sectional view of the prosthetic heart valve of FIG. 4 showing a commissure attachment feature in accordance with an embodiment of the present invention;



FIG. 6 is a flow chart showing a method of manufacturing the prosthetic heart valve of FIG. 4; and



FIG. 7 is a highly schematic fragmentary view of the stent of the prosthetic heart valve of FIG. 4.





DETAILED DESCRIPTION

As used herein, the term “proximal,” when used in connection with a prosthetic heart valve, refers to the end of the heart valve closest to the heart when the heart valve is implanted in a patient, whereas the term “distal,” when used in connection with a prosthetic heart valve, refers to the end of the heart valve farthest from the heart when the heart valve is implanted in a patient. As used herein, the terms “generally,” “substantially,” “approximately” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified.



FIG. 1 illustrates a collapsible prosthetic heart valve 10 that is designed to replace the function of the native aortic valve of a patient. Prosthetic heart valve 10 includes an expandable stent 12 which may be formed from biocompatible materials that are capable of self-expansion, for example, shape memory alloys such as nitinol. Stent 12 extends from a proximal or annulus end 14 to a distal or aortic end 16, and includes an annulus section 18 adjacent the proximal end and an aortic section 20 adjacent the distal end. Annulus section 18 has a relatively small cross-section in an expanded condition compared to aortic section 20 in the expanded condition. Annulus section 18 may be in the form of a cylinder having a substantially constant diameter along its length. A transition section 22 tapers outwardly from annulus section 18 to aortic section 20. Each of the sections of stent 12 includes a plurality of struts 24 which form a plurality of cells 26 that are connected to one another in one or more annular rows around the stent. Annulus section 18 may have two annular rows of complete cells and aortic section 20 and transition section 22 may each have one or more annular rows of partial cells. The cells in aortic section 20 may be larger than the cells in annulus section 18. The larger cells in aortic section 20 facilitate positioning prosthetic valve 10 within the native aortic annulus such that stent 12 does not interfere with blood flow to the coronary arteries.


Stent 12 includes one or more retaining elements 28 at distal end 16. Retaining elements 28 are sized to cooperate with a corresponding retaining structure on a delivery device. This cooperation minimizes axial movement of the prosthetic heart valve relative to the delivery device during unsheathing or resheathing procedures, and prevents rotation of the prosthetic heart valve relative to the delivery device as the delivery device is advanced to the target location and during deployment.


Stent 12 may also include a plurality of commissure attachment features 30 for attaching the commissure between two adjacent leaflets to the stent. As shown in FIG. 1, commissure attachments features 30 are disposed within the wall of stent 12 and may lie at the intersection of four cells 26, two of the cells being adjacent to one another in the same annular row, and the other two cells being in different annular rows and lying in end-to-end relationship. Commissure attachment features 30 are preferably positioned entirely within annulus section 18, or at the juncture of the annulus section and transition section 22. Commissure attachment features 30 may include one or more eyelets 32 which facilitate the suturing of the leaflet commissure to stent 12.


Prosthetic heart valve 10 also includes a valve assembly 34, which may be positioned entirely within annulus section 18 and secured to stent 12 by suturing the valve assembly to struts 24 and/or to commissure attachment features 30. That is, the entire valve assembly 34 may be axially positioned between the proximal end 14 of stent 12 and commissure attachment features 30, such that none of the valve assembly is positioned between the commissure attachment features and the distal end 16 of the stent. Valve assembly 34 includes a cuff 36 and a plurality of leaflets 38 which open and close collectively to function as a one-way valve. Both cuff 36 and leaflets 38 may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or biocompatible polymers, such as PTFE, urethanes and the like.


Prosthetic heart valve 10 may be used to replace a native valve, a surgical heart valve or a heart valve that has undergone a surgical procedure. Prosthetic heart valve 10 may be delivered to the desired site (e.g., near the native aortic annulus) using any suitable delivery device. During delivery, prosthetic heart valve 10 is disposed inside the delivery device in a collapsed condition. The delivery device may be introduced into a patient using a transfemoral, transapical, transseptal or any other percutaneous approach. Once the delivery device has reached the target site, the user may deploy prosthetic heart valve 10. Upon deployment, prosthetic heart valve 10 expands so that the annulus section 18 of stent 12 is in secure engagement within the native annulus.



FIG. 2 is a highly schematic cutaway view showing prosthetic heart valve 10 disposed within the native aortic annulus of a patient. When prosthetic heart valve 10 is properly positioned within the native annulus, it works as a one-way valve, allowing blood to flow from the left ventricle of the heart to the aorta during systole, and preventing blood from flowing in the opposite direction. Long term clinical success, and ultimately the life of prosthetic heart valve 10 is dependent, in part, on the ability of the free edges of leaflets 38 to properly coapt. Thrombus buildup in the neo-sinus NS of prosthetic heart valve 10 may restrict motion of leaflets 38 and prevent the leaflets from coapting.


Suturing the commissures of leaflets 38 radially inward of the commissure attachments features 30 of stent 12, as shown in FIG. 3, reduces the cross-sectional area of the lumen of prosthetic heart valve 10, and results in increased velocity of blood flow through the neo-sinus during systole. The increased blood flow velocity is believed to improve blood wash out from the neo-sinus and reduce thrombus build up. However, the addition of sutures S places additional strain on the leaflets 38 of valve assembly 34 and increases the likelihood that the valve assembly will fail at this junction. Failure may, for example, include tearing of sutures S and/or the leaflets 38 of valve assembly 34.



FIG. 4 illustrates a prosthetic heart valve 110 according to an embodiment of the present invention. Prosthetic heart valve 110 includes all of the features of prosthetic heart valve 10, except for commissure attachment features 30. Accordingly, each of the features of prosthetic heart valve 110 that correspond to features of prosthetic heart valve 10 are not described again hereinafter. Instead, when such features are referenced or illustrated in FIGS. 4-7, these features are described and illustrated using corresponding 100 series numerals.


Prosthetic heart valve 110 replaces commissure attachment features 30 with commissure attachment features 130, shown in FIG. 5. Commissure attachment features 130 are designed to redistribute strain from the leaflets 138 of prosthetic heart valve 110 to the stent 112 of the prosthetic heart valve. Commissure attachment features 130 are spaced apart from one another in an annular direction of stent 112 and disposed within a predetermined one of the annular rows of cells 126. Preferably, commissure attachment features 130 are disposed in one of the rows of cells within the annulus section 118 of stent 112, or in one of the rows of cells at the juncture of the annulus section and the transition section 122 of the stent. Since FIG. 4 illustrates a prosthetic heart valve 110 for replacing a native tricuspid valve, such as the aortic valve, prosthetic heart valve 110 is illustrated with three leaflets 138, as well as three commissure attachment features 130. However, it will be appreciated that prosthetic heart valves according to this aspect of the invention may have a greater or lesser number of leaflets 138 and/or commissure attachment features 130. For example, if prosthetic heart valve 110 were a prosthetic heart valve for replacing a native bicuspid valve, such as a mitral valve, the prosthetic heart valve may include two commissure attachment features 130 for attaching each of the two prosthetic leaflets 138 to stent 112.


Referring to FIG. 5, each one of the plurality of commissure attachment features 130 includes a body 140 that has a length in a longitudinal direction of stent 112, a width in a radial direction of the stent and a thickness (not shown) in an annular direction of the stent, the width being greater than the thickness. The width of body 140 may be about 3.0 mm or less, and is preferably between about 2.0 mm and about 2.5 mm. Commissure attachment features 130 may be positioned above the bulk of leaflets 138. In light of this and that the commissure attachment features have a relatively small dimension in the medial direction of stent 112, the collapsibility of prosthetic heart valve 110 is not inhibited. Accordingly, prosthetic heart valve 110 can be collapsed into a competitive French delivery system, for example, an 18 French delivery device.


The body 140 of commissure attachment feature 130 has a side 142 that is attached to select struts 124 of stent 112, and a free edge 144 that is disposed in an interior region the stent. That is, the body 140 of commissure attachment feature 130 extends from select struts 124 in a medial direction of stent 112 (i.e., toward the middle of the stent or radially inward). In other words, body 140 extends orthogonal to the annular direction of stent 112 toward the center of the stent. The body 140 of commissure attachment feature 130 may be shaped as a quarter ellipse, or a quarter circle, such that the free edge 144 of the body forms an arc extending from a distal end of the attached side 142 of the body to a proximal end of the free edge spaced radially inward from stent 112.


The body 140 of commissure attachment feature 130 may include a plurality of apertures or eyelets for connecting valve assembly 134 to stent 112. Thus, body 140 may include an eyelet 146 for coupling cuff 136 to stent 112, and one or more smaller eyelets 148 for suturing adjacent leaflets 138 to one another and to the commissure attachment feature. At least one of leaflet attachment eyelets 148 may be spaced from the attached side 142 of commissure attachment feature 130 so as to be spaced from a luminal surface of stent 112.



FIG. 6 is a flow chart depicting a method 200 of manufacturing prosthetic heart valve 110. In a first step 202, a tube of nitinol is placed around a mandrel and cut, preferably by a laser or other technique, to form stent 112. A fragmentary view of stent 112 after the tube has been cut and radially expanded is illustrated in FIG. 7. As shown, commissure attachment features 130 initially extend in a lateral direction relative to the struts 124 of stent 112. That is, commissure attachment features 130 initially lie within the circumference of stent 112. In a next step 204, the user may bend commissure attachment features 130 from their initial positions (e.g., the lateral or circumferential direction) to final positions (e.g., the medial or radial direction) as shown in FIG. 5. Commissure attachment features 130 are then heat set, or otherwise permanently set, in this position.


After commissure attachment features 130 are set in their final positions, cuff 136 may be attached to stent 112 in step 206, for example, by suturing the cuff to the stent. Although not required, a suture may additionally be pierced through cuff 136 and passed through the cuff attachment eyelet 146 of commissure attachment feature 130 before the suture is again pierced through the cuff. This additional step may optionally be repeated for each one of commissure attachment features 130. The ends of adjacent leaflets may then be sutured together and coupled to the commissure attachment feature 130. In this step 208, a suture may pierce through a first one of the leaflets, pass through at least one of the leaflet attachment eyelets 148 of commissure attachment feature 130, and then pierce through an adjacent leaflet. In a final step 210, the belly of each one of leaflets 138 may then be sutured to cuff 136 and stent 112. In an exemplary embodiment, a series of suture loops extend along the belly of each one of the leaflets in a parabolic shape, and further secure the leaflets to the stent.


By connecting the leaflet commissures to commissure attachment feature 130 at a position spaced medially inward from stent 112, the cross-sectional area of the lumen of prosthetic heart valve 110 is reduced, such that the velocity of blood flow through the lumen during systole will be increased. As a result of the increased blood flow velocity, some of the blood will form an eddy in the neo-sinus, and wash out from the neo-sinus is improved and thrombus build up is reduced. Moreover, because adjacent leaflets are sutured together via medially extending commissure attachment features 130, when a stress is applied to the prosthetic valve leaflets 138, the stress is transferred away from the prosthetic leaflets to the commissure attachment features and stent 112. This reduces the likelihood that valve assembly 134 will fail under stress and prolongs the life of prosthetic heart valve 110.


To summarize the foregoing, a prosthetic heart valve, includes a stent extending in a longitudinal direction and having a collapsed condition and an expanded condition, the stent including a plurality of struts forming cells and a plurality of commissure attachment features spaced apart in an annular direction of the stent, each of the commissure attachment features being attached to select ones of the struts and extending in a medial direction of the stent; and a valve assembly secured to the plurality of the commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position; and/or


each of the commissure attachment features may extend substantially orthogonal to the annular direction of the stent; and/or


the stent and the commissure attachment features may be integrally formed; and/or


the stent and the commissure attachment features may be formed of nitinol; and/or


each one of the commissure attachment features may be located in the annulus section of the stent and/or a width of the commissure attachment feature in the medial direction is about 3.0 mm or less; and/or


a width of the commissure attachment feature in the medial direction may be between about 2.0 mm and about 2.5 mm; and/or


the commissure attachment feature may include an eyelet; and/or


the eyelet may be spaced in the medial direction from a luminal surface of the stent; and/or


the cuff may be disposed on a luminal surface of the stent; and/or


two of the leaflets may be sutured to each of the commissure attachment features; and/or


each of the commissure attachment features may have a side attached to the stent and an arcuate edge extending between a distal end of the side and a proximal end of the arcuate edge spaced in the medial direction from the stent; and/or


the stent may include three of the commissure attachment features; and/or


the cells may be connected to one another in a plurality of annular rows about the stent, each one of the plurality of commissure attachment features being disposed in a predetermined one of the annular rows.


A method of manufacturing a prosthetic heart valve is also provided. The method includes cutting a tubular material to form a stent, the stent extending in a longitudinal direction and having a collapsed condition and an expanded condition, the stent including a plurality of struts forming cells and a plurality of commissure attachment features spaced apart in an annular direction of the stent; bending each of the commissure attachment features from a first orientation to a second orientation different from the first orientation; and coupling a valve assembly to the commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position; and/or


the first orientation may be an annular direction of the stent and the second orientation may be a medial direction of the stent; and/or


the coupling step may comprise suturing each commissure formed by adjacent ones of the leaflets to a respective one of the commissure attachment features; and/or


the method may further comprise suturing a belly of each one of the leaflets to the cuff and the stent; and/or


the tubular material may be nitinol; and/or


the method may further comprise heat setting the nitinol after the bending step.


Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.

Claims
  • 1. A prosthetic heart valve, comprising: an expandable stent extending in a longitudinal direction and having an annulus section and an aortic section, the stent including a plurality of struts forming cells and a plurality of commissure attachment features spaced apart from one another in an annular direction of the stent, each of the commissure attachment features being attached to select ones of the struts in the annulus section and having a length in the longitudinal direction, a thickness in the annular direction, and a width extending from the select ones of the struts in a radial direction of the stent toward a longitudinal axis of the stent, the width being greater than the thickness; anda valve assembly secured to the plurality of the commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position.
  • 2. The valve of claim 1, wherein the stent and the commissure attachment features are integrally formed.
  • 3. The valve of claim 1, wherein the stent and the commissure attachment features are formed of nitinol.
  • 4. The valve of claim 1, wherein the width of each of the commissure attachment features in the radial direction is about 3.0 mm or less.
  • 5. The valve of claim 1, wherein the width of each of the commissure attachment features in the radial direction is between about 2.0 mm and about 2.5 mm.
  • 6. The valve of claim 1, wherein each of the commissure attachment features includes an eyelet.
  • 7. The valve of claim 6, wherein the eyelet is spaced in the radial direction from a luminal surface of the stent.
  • 8. The valve of claim 1, wherein the cuff is disposed on a luminal surface of the stent.
  • 9. The valve of claim 1, wherein two of the leaflets are sutured to each of the commissure attachment features.
  • 10. The valve of claim 1, wherein each of the commissure attachment features has a side attached to the stent and an arcuate edge extending between a distal end of the side and a proximal end of the arcuate edge spaced in the radial direction from the stent.
  • 11. The valve of claim 1, wherein the stent includes three of the commissure attachment features.
  • 12. The valve of claim 1, wherein the cells are connected to one another in a plurality of annular rows about the stent, each of the commissure attachment features being disposed in a predetermined one of the annular rows.
  • 13. A prosthetic heart valve, comprising: an expandable stent extending in a longitudinal direction, the stent including a plurality of struts forming cells and a plurality of commissure attachment features spaced apart in an annular direction of the stent, each of the commissure attachment features being attached to select ones of the struts and having opposing major surfaces defining an eyelet therethrough, the opposing major surfaces each having a width extending in a radial direction of the stent so as to extend from the select ones of the struts toward a longitudinal axis of the stent, and the opposing major surfaces being separated by a thickness extending in the annular direction of the stent, the width being grater than the thickness; anda valve assembly secured to the plurality of the commissure attachment features, the valve assembly including a cuff and a plurality of leaflets, each of the leaflets having a free edge and being capable of alternating between an open position and a closed position.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims the benefit of U.S. Provisional Application Ser. No. 62/880,758, filed Jul. 31, 2019, entitled Alternate Stent CAP Design for TAVR, the disclosure of which is hereby incorporated herein by reference.

US Referenced Citations (159)
Number Name Date Kind
3657744 Ersek Apr 1972 A
4275469 Gabbay Jun 1981 A
4491986 Gabbay Jan 1985 A
4759758 Gabbay Jul 1988 A
4878906 Lindemann et al. Nov 1989 A
4922905 Strecker May 1990 A
4994077 Dobben Feb 1991 A
5411552 Andersen et al. May 1995 A
5415664 Pinchuk May 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5843167 Dwyer et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5910170 Reimink et al. Jun 1999 A
5935163 Gabbay Aug 1999 A
5961549 Nguyen et al. Oct 1999 A
6077297 Robinson et al. Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6090140 Gabbay Jul 2000 A
6214036 Letendre et al. Apr 2001 B1
6264691 Gabbay Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6368348 Gabbay Apr 2002 B1
6419695 Gabbay Jul 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6488702 Besselink Dec 2002 B1
6517576 Gabbay Feb 2003 B2
6533810 Hankh et al. Mar 2003 B2
6582464 Gabbay Jun 2003 B2
6610088 Gabbay Aug 2003 B1
6623518 Thompson et al. Sep 2003 B2
6685625 Gabbay Feb 2004 B2
6719789 Cox Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6783556 Gabbay Aug 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6869444 Gabbay Mar 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
7018406 Seguin et al. Mar 2006 B2
7025780 Gabbay Apr 2006 B2
7137184 Schreck Nov 2006 B2
7160322 Gabbay Jan 2007 B2
7247167 Gabbay Jul 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7311730 Gabbay Dec 2007 B2
7374573 Gabbay May 2008 B2
7381218 Schreck Jun 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7510572 Gabbay Mar 2009 B2
7524331 Birdsall Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7585321 Cribier Sep 2009 B2
7682390 Seguin Mar 2010 B2
7731742 Schlick et al. Jun 2010 B2
7803185 Gabbay Sep 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7914569 Nguyen et al. Mar 2011 B2
D648854 Braido Nov 2011 S
D652926 Braido Jan 2012 S
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
D653342 Braido et al. Jan 2012 S
D653343 Ness et al. Jan 2012 S
D654169 Braido Feb 2012 S
D654170 Braido et al. Feb 2012 S
D660432 Braido May 2012 S
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
D684692 Braido Jun 2013 S
8840661 Manasse Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
9700442 White Jul 2017 B2
10004597 Li Jun 2018 B2
11020221 Arcaro Jun 2021 B2
20020036220 Gabbay Mar 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20040049262 Obermiller et al. Mar 2004 A1
20040093075 Kuehne May 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20050096726 Sequin et al. May 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050240200 Bergheim Oct 2005 A1
20050256566 Gabbay Nov 2005 A1
20060008497 Gabbay Jan 2006 A1
20060074484 Huber Apr 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060173532 Flagle et al. Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060195180 Kheradvar et al. Aug 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060241744 Beith Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060259120 Vongphakdy et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070067029 Gabbay Mar 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100435 Case et al. May 2007 A1
20070118210 Pinchuk May 2007 A1
20070198097 Zegdi Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080021552 Gabbay Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080114452 Gabbay May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255662 Stacchino et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20090099653 Suri et al. Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100049306 House et al. Feb 2010 A1
20100087907 Lattouf Apr 2010 A1
20100131055 Case et al. May 2010 A1
20100168778 Braido Jul 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110029072 Gabbay Feb 2011 A1
20120303116 Gorman, III et al. Nov 2012 A1
20140005776 Braido Jan 2014 A1
20190091014 Arcaro et al. Mar 2019 A1
20210259833 Maimon Aug 2021 A1
Foreign Referenced Citations (17)
Number Date Country
19857887 Jul 2000 DE
10121210 Nov 2005 DE
102005003632 Aug 2006 DE
202008009610 Dec 2008 DE
0850607 Jul 1998 EP
1000590 May 2000 EP
1360942 Nov 2003 EP
1584306 Oct 2005 EP
1598031 Nov 2005 EP
1926455 Jun 2008 EP
2850008 Jul 2004 FR
2847800 Oct 2005 FR
9930646 Jun 1999 WO
02067782 Sep 2002 WO
2005070343 Aug 2005 WO
07071436 Jun 2007 WO
08070797 Jun 2008 WO
Non-Patent Literature Citations (17)
Entry
International Search Report for Application No. PCT/US2020/042776 dated Oct. 16, 2020, 2 pages.
Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR—dated May 25, 2010.
“Percutaneous Aortic Valve Replacement: Resection Before Implantation”, Quaden, Rene et al., European J. of Cardio-Thoracic Surgery, vol. 27, No. 5, May 2005, pp. 836-840.
Braido, et al., U.S. Appl. No. 29/375,243, filed Sep. 20, 2010, titled “Surgical Stent Assembly”.
“Catheter-Implanted Prosthetic Heart Valves: Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta in Isolated Vessels and Closed Chest Pigs”, Knudsen et al., The International Journal of Artificial Organs, vol. 16, No. 5, May 1993, pp. 253-262.
“Transluminal Aortic Valve Placement. A Feasability Study with a Newly Designed Collapsible Aortic Valve”, Moazami et al., ASAIO Journal, vol. 42, No. 5, 1996, pp. M381-M385.
“Transluminal Catheter Implanted Prosthetic Heart Valves”, Andersen, H. R., International Journal of Angiology, vol. 7, No. 2, Mar. 1998, pp. 102-106.
“Transluminal Implantation of Artificial Heart Valves”, Andersen, H. R., et al., European Heart Journal, vol. 13, No. 5, May 1992, pp. 704-708.
Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008.
“Direct-Access Valve Replacement”, Christoph H. Huber, et al., Journal of the American College of Cardiology, vol. 46, No. 2, (Jul. 19, 2005).
“Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, John G. Webb et al., Circulation, 2006; 113:842-850 (Feb. 6, 2006).
“Minimally invasive cardiac surgery”, M. J. Mack, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Mar. 23, 2006).
“Transapical Transcatheter Aortic Valve Implantation in Humans”, Samuel V. Lichtenstein et al., Circulation. 2006; 114: 591-596 (Jul. 31, 2006).
“Closed Heart Surgery: Back to the Future”, Samuel V. Lichtenstein, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, May 2006, pp. 941-943.
“Transapical Approach for Sutureless Stent-Fixed Aortic Valve Implantation: Experimental Results”, Th. Walther et al., European Journal of Cardio-Thoracic Surgery, vol. 29, No. 5, May 2006, pp. 703-708.
“Transapical aortic valve implantation: an animal feasibility study”; Todd M. Dewey et al., The annals of thoracic surgery 2006; 82: 110-6 (Feb. 13, 2006).
Transcatheter Valve Repair, Hijazi et al., CRC Press, Jan. 2006, pp. 165-186.
Related Publications (1)
Number Date Country
20210030536 A1 Feb 2021 US
Provisional Applications (1)
Number Date Country
62880758 Jul 2019 US